Actively Recruiting

Phase 2
Age: 18Years +
MALE
NCT06932458

A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases

Led by Western University, Canada · Updated on 2025-07-20

30

Participants Needed

1

Research Sites

254 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%). For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients

CONDITIONS

Official Title

A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients (>18 years) with pure seminoma confirmed by orchiectomy.
  • Clinical stage I with retroperitoneal relapse or de novo clinical stage II at presentation.
  • Imaging showing no more than 2 enlarged retroperitoneal lymph nodes, each ≤3 cm, within 8 weeks before surgery.
  • Suitable for bilateral nerve-sparing RPLND surgery.
  • Normal serum tumor markers (AFP, HCG, LDH) within 2 weeks before surgery.
Not Eligible

You will not qualify if you...

  • Any medical condition making surgery too risky as judged by the surgeon.
  • Presence of any non-seminoma component in the orchiectomy specimen.
  • AFP level above 20 at any time before or after orchiectomy.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

London Health Sciences Centre

London, Ontario, Canada

Actively Recruiting

Loading map...

Research Team

K

Kaydee Connors

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here